Glenmark gains favourable arbitration ruling in crofelemer case with Napo
This article was originally published in Scrip
An international arbitrator has ruled in favour of Glenmark Pharmaceuticals upholding, among others, the Indian firm's commercialisation rights to Napo Pharmaceuticals' anti-secretory gastrointestinal agent, crofelemer
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.
Remogliflozin prescriptions gallop in India and Glenmark expects the ‘affordable’ therapy to take share from other SGLT2 inhibitors.